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Background 
Intensive insulin therapy reduces morbidity and mortality in 
patients in surgical intensive care units (ICUs), but its role in 
patients in medical ICUs is unknown. 
Methods 
Objective: To investigate the efficacy of intensive insulin 
therapy in medical ICU patients. 
Design: Prospective, randomized, controlled trial 
Setting: Medical ICU in Leuven, Belgium. 
Subjects:  1200 medical ICU patients anticipated to need 
intensive care for at least three days. 
Intervention:  On admission, patients were randomly 
assigned to strict normalization of blood glucose levels (80 
to 110 mg per deciliter [4.4 to 6.1 mmol per liter]) with the 
use of insulin infusion or to conventional therapy (insulin 
administered when the blood glucose level exceeded 215 
mg per deciliter [12 mmol per liter], with the infusion tapered 
when the level fell below 180 mg per deciliter [10 mmol per 
liter]).  
Measurements and main results: There was a history of 
diabetes in 16.9 percent of the patients. In the intention-to-
treat analysis of 1200 patients, intensive insulin therapy 
reduced blood glucose levels but did not significantly reduce 
in-hospital mortality (40.0 percent in the conventional-
treatment group vs. 37.3 percent in the intensive-treatment 
group, P=0.33). However, morbidity was significantly 
reduced by the prevention of newly acquired kidney injury, 
accelerated weaning from mechanical ventilation, and 
accelerated discharge from the ICU and the hospital. 
Although length of stay in the ICU could not be predicted on 
admission, among 433 patients who stayed in the ICU for 
less than three days, mortality was greater among those 
receiving intensive insulin therapy. In contrast, among 767 
patients who stayed in the ICU for three or more days, in-
hospital mortality in the 386 who received intensive insulin 
therapy was reduced from 52.5 to 43.0 percent (P=0.009) 
and morbidity was also reduced. 
Conclusion 
Intensive insulin therapy significantly reduced morbidity but 
not mortality among all patients in the medical ICU. 
Although the risk of subsequent death and disease was 
reduced in patients treated for three or more days, these 
patients could not be identified before therapy. Further 
studies are needed to confirm these preliminary data. 
(ClinicalTrials.gov number, NCT00115479). 
Commentary 
In 2001, Van den Berghe and colleagues published a 
seminal trial, which demonstrated that tight glycemic control 
(blood glucose concentration between 80-110 mg/dL) 
resulted in absolute reductions in ICU and hospital mortality 
of 3.4% and 3.7%, respectively, for surgical ICU patients [2]. 
The results of this trial led to the integration of tight glycemic 
control, also known as intensive insulin therapy (IIT), into 
various practice guidelines and quality of care indices. The 
results of this trial also prompted this obvious question: 
would implementation of the same protocol also improve 
outcome for medical ICU patients?   
The current study by Van den Berghe and colleagues 
begins to address this question [1]. The authors randomized 
1200 medical ICU patients to strict normalization of blood 
glucose levels (80 to 110 mg/dL) with the use of insulin 
infusion or to conventional therapy with a more liberal blood 
glucose target (180-200 mg/dL). The groups were equally 
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balanced with respect to age, sex, comorbid conditions, 
reasons for admissions and history of diabetes. The results 
of the study were surprising; there was no mortality benefit 
for IIT and there was a significantly greater occurrence of 
hypoglycemia in the IIT group (18.7% vs. 3.1%, p<0.001). 
Those with hepatic or renal failure appeared to be at 
greatest risk of hypoglycemia. Countering these 
disappointing findings were improvements in several 
important secondary outcomes with IIT, including reductions 
in newly acquired kidney injury, earlier weaning from 
mechanical ventilation, and reduced ICU and hospital length 
of stay.  
The study has several strengths including a randomized 
controlled design and an intention-to-treat analysis. 
Limitations include its unblinded nature and its single-center 
design. In the subgroup of patients who were in the ICU for 
fewer than three days, IIT appeared to result in a higher 
mortality rate (26.8% vs. 18.8%). The significance of this 
finding varied depending on the authors’ statistical analysis; 
a Chi square test demonstrated a borderline statistically 
significant result (p=0.05), whereas both uncorrected and 
corrected proportional hazards analyses were insignificant 
(p=0.35 and p=0.41, respectively). Notably, the subgroup 
with ICU stays of three or more days had significantly lower 
hospital mortality with IIT (43.0% vs. 52.5%, p=0.009), 
although this group could not be reliably identified at study 
entry. As always, one must be cognizant of the dangers of 
subgroup analyses [3]. 
The results of this study differ significantly from those of the 
surgical ICU study [2]. Although it is tempting to compare 
the two trials, there are several differences between the 
study populations, most notably the severity of illness, which 
was much higher in the medical ICU study. There may be 
other reasons to account for the divergent results, including 
treatment differences between the two populations due to 
secular changes in intensive care practices, such as the use 
of steroids for relative adrenal insufficiency; the role of 
hyperglycemia in post-surgical infections; and the 
percentage of patients with hypoglycemia. In the current 
study, the authors identified hypoglycemia as an 
independent risk factor for death, though it did not appear to 
be directly responsible for the excess of deaths observed 
with IIT in those with ICU stays of less than three days. 
However, it remains plausible that the short-term benefits of 
IIT may be outweighed by the risks, death or otherwise, that 
hypoglycemia confers.  
Two large ICU-based IIT trials, both of which were stopped 
early for lack of efficacy and safety concerns, highlight the 
issue of hypoglycemia with IIT. The German VISEP 
(Volume Substitution and Insulin Therapy in Severe Sepsis) 
study, a multicenter trial designed to examine the effects of 
colloid versus crystalloid volume resuscitation and an 
intensive insulin therapy regimen, was stopped after 
recruiting 488 out of a planned 600 subjects because of 
frequent hypoglycemia in the IIT arm (12.1% vs. 2.1%, 
p<0.001) and no difference in mortality [4]. Similarly, the 
GLUCONTROL (Comparing the Effects of Two Glucose 
Control Regimens by Insulin in Intensive Care Unit Patients) 
study, a multicenter, international study of IIT in mixed ICU 
populations, was stopped after recruiting 1101 of the 
planned 3500 subjects [5]. In this study, severe 
hypoglycemia (defined as blood glucose < 40 mg/dL) 
occurred more frequently in IIT subjects (8.6% vs. 2.4%, 
p<0.001). Furthermore, there were no differences in 
mortality (17% vs. 15%, p=NS) or length of stay.  
One additional trial of IIT in the ICU is ongoing. NICE-
SUGAR (Normoglycaemia in Intensive Care Evaluation and 
Survival Using Glucose Algorithm Regulation) is a 
multicenter, international study evaluating glucose 
management at two different levels (81-108 mg/dL vs. 144-
180 mg/dL) in a heterogeneous group of critically ill patients 
in the ICU for at least one day [6]. The primary outcome is 
90-day mortality. As of early 2007, 3000 of a planned 6100 
subjects were enrolled. In August 2006, the study’s Data 
and Safety Monitoring Board reviewed the interim results of 
the first 2000 patients, determining that the study should 
continue and that there was no reason for the interim 
analysis to be unblinded [7]. An additional interim analysis 
will be conducted when follow-up of 4000 patients is 
available, estimated to be mid-2007. 
Recommendation 
The best available evidence suggests that IIT may be an 
important treatment modality in certain critically ill patient 
populations, such as those who have undergone cardiac 
surgery [8] or other operative procedures [2]. We have 
reservations, however, in applying these same protocols to 
heterogeneous medical ICU populations given the negative 
results of this and other trials and the attendant risks of 
prolonged, unrecognized hypoglycemia. Clearly, real-time 
glucose monitoring systems have the potential to reduce 
this risk, but none are clinically available at this time. While 
awaiting the results of NICE-SUGAR, clinicians should 
carefully consider the potential risks and benefits when 
implementing IIT in medical ICU patients and may well be 
advised to avoid this treatment modality in those with 
hepatic or renal failure. 
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